5-Amino-1MQ vs Tirzepatide
Side-by-side comparison of 5-Amino-1MQ and Tirzepatide: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
5-Amino-1MQ
Tirzepatide
5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide to…
Lowest listed price: $29.99 across 14 listings
Full 5-Amino-1MQ profileTirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid…
Lowest listed price: $49.00 across 14 listings
Full Tirzepatide profileSide-by-side comparison
| Attribute | 5-Amino-1MQ | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Metabolic & Weight Loss |
| Research Stage | Preclinical | FDA Approved |
| Mechanism of Action | 5-Amino-1MQ works by inhibiting nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to the nitrogen of nicotinamide (vitamin B3 amide), producing 1-methylnicotinamide (1-MNA) and… | Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… |
| Half-Life | ~6–12 hours (oral) | ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification |
| Typical Dose Range | 50 mg - 150 mg daily (oral or injection) | 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose |
| Dosing Frequency | Once daily oral | Once weekly subcutaneous injection |
| Administration | Oral | Subcutaneous (weekly) |
| Side Effects | The side effect profile of 5-amino-1MQ in humans is not documented because there are no human clinical trials. Rodent studies report generally good tolerability at doses producing metabolic and muscle benefits, without obvious signs of hepatotoxicity,… | Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. |
| Molecular Weight | 159.21 g/mol | 4813.5 Da |
| Common Vial Sizes | 50mg capsules, 100mg capsules | 5mg, 10mg, 15mg |
Price History
5 data points- OF
- BM
- Half Nattys
- Ion Peptide
- Disguised Alpha
- RC
- LB
Price History
3 data points- BM
- Half Nattys
- Ion Peptide
5-Amino-1MQ: potential benefits
- Enhanced fat metabolism and weight loss
- Increased NAD+ levels in adipose tissue
- Improved cellular energy production
- Anti-aging properties via sirtuin activation
Tirzepatide: potential benefits
- Mean body weight reduction of 22.5% at 72 weeks - highest of any anti-obesity medication (PMID: 35658024)
- 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
- Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415)
- Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
- Dual incretin mechanism providing complementary metabolic benefits
- Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
- Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
Frequently asked
What's the difference between 5-Amino-1MQ and Tirzepatide?
5-Amino-1MQ is a weight loss that 5-amino-1mq works by inhibiting nicotinamide n-methyltransferase (nnmt), an enzyme that catalyzes the transfer of a methyl group from s-adenosyl-l-methionine (sam) to the nitrogen…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (~6–12 hours (oral) vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range.
Which has the longer half-life, 5-Amino-1MQ or Tirzepatide?
5-Amino-1MQ has a half-life of ~6–12 hours (oral). Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, 5-Amino-1MQ or Tirzepatide?
Lowest listed price on BodyHackGuide: 5-Amino-1MQ from $29.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack 5-Amino-1MQ and Tirzepatide?
Stacking depends on mechanism overlap, safety profile, and goals. 5-Amino-1MQ and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy 5-Amino-1MQ or Tirzepatide
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.